Day #118 - Probable Leptospirosis

Today we heard a case of a returning traveller who suffered complete cardiorespiratory collapse as part of a sepsis syndrome. In this syndrome the patient was hypotensive requiring inopressors, hypoxemic/hypercapnic requiring ventillation, coagulopathic with a microangiopathic hemolytic anemia (see TTP blog and previous anemia/thrombocytopenia blogs) from DIC, and in acute renal failure. In the context of this illness he suffered either myocarditis or a myocardial infarction related to hypoperfusion.

This was as sick as anyone can be and survive and it is a testiment to our critical care system that he did indeed survive.

We spent time discussing the approach to diarrhea, which was his initial presenting symptom.

---

We then defined sepsis

SIRS Criteria:

• Fever or hypothermia
  
• WBC >12,000 or less than 4,000
• HR >90
• RR >20

Sepsis = 2 or more SIRS criteria of presumed infective etiology
Severe sepsis includes sepsis with end organ dysfunction or lactate >4
Septic shock includes severe sepsis with refractory hypotension requiring inopressors

We then talked about the approach to early goal directed therapy in sepsis.

In this case, I believe early appropriate antibiotic therapy would include:

• Vancomycin (in case of community associated MRSA in a young man)
• Meropenem (to cover streptococcus, gram negatives including ESBL/drug resistant)
• Doxycycline to cover leptospirosis

In general, in a critically ill patient like this, I will draw cultures and then use very broad spectrum coverage empirically with a plan to de-escallate when culture results are available

---

The etiology in this case is unclear but I wonder about leptospirosis. I didn't really want to talk about leptospirosis in detail during the case presentation.... This is the case of leptospirosis in NEJM that I elluded to.

I have provided you with a copy of a talk I once gave on leptospirosis here.

---

Free tidbits:

Here is an article on fever in the returning traveller
A good review of typhoid fever is here.